There is no single “best” medication for vascular dementia because no drug has been approved specifically to treat it. Unlike Alzheimer’s disease, which has several targeted therapies, vascular dementia is managed with a combination of off-label cognitive medications and aggressive control of the cardiovascular risk factors that caused the damage in the first place. That second part, managing blood pressure, cholesterol, and blood sugar, is arguably more important than any cognitive drug currently available.
Why No Drug Is FDA-Approved for Vascular Dementia
Vascular dementia results from reduced blood flow to the brain, usually due to strokes or chronic small-vessel disease. The underlying cause is vascular, not a single protein buildup like the amyloid plaques targeted in Alzheimer’s treatments. This makes it harder to develop a drug aimed at one clear mechanism, and clinical trials have struggled to show large enough cognitive benefits to earn regulatory approval. What doctors prescribe instead are medications originally developed for Alzheimer’s, used off-label based on the best available evidence.
Cholinesterase Inhibitors: Modest Cognitive Benefits
The most commonly prescribed cognitive medications for vascular dementia are cholinesterase inhibitors, drugs that boost levels of a brain chemical involved in memory and attention. Three are available: donepezil, galantamine, and rivastigmine. A large Cochrane network review compared all three and found that donepezil at a higher dose (10 mg) had the greatest effect on cognition, improving scores on a standard 70-point cognitive test by about 2.2 points compared to placebo. Galantamine performed similarly, with roughly a 2-point improvement.
Those numbers sound small, and the review’s authors were straightforward about it: the improvements are statistically real but may not be clinically meaningful for most people. You or a family member might not notice a dramatic difference in daily life. Rivastigmine showed essentially no measurable cognitive benefit in the available data.
The higher dose of donepezil comes with more side effects, primarily nausea, diarrhea, and loss of appetite, which are common with all cholinesterase inhibitors. The review noted that while donepezil 10 mg had the strongest cognitive signal, it also carried the highest rate of adverse effects. For some people, the lower 5 mg dose or galantamine may offer a better balance between modest benefit and tolerability. Despite the limited effect sizes, these medications remain an option worth discussing simply because no better alternatives exist for the cognitive symptoms themselves.
Memantine: Stabilizing Rather Than Improving
Memantine works differently from cholinesterase inhibitors. It regulates a brain signaling system involved in learning and memory that can become overactive and damage neurons. In a 28-week trial of people with mild to moderate vascular dementia, those taking memantine gained an average of 0.4 points on a cognitive scale while the placebo group declined by 1.6 points, a net difference of 2 points. Memantine also showed benefits on a mini mental status exam and on measures of intellectual function and disruptive behavior.
The practical takeaway is that memantine appears to slow cognitive decline rather than reverse it. In a condition where the trajectory is generally downward, stabilization has real value. Some doctors prescribe memantine alongside a cholinesterase inhibitor, though the evidence for combining them in vascular dementia specifically is limited.
Blood Pressure Control: The Most Impactful Intervention
Because vascular dementia is caused by blood vessel damage in the brain, controlling the factors that harm blood vessels does more to slow progression than any cognitive drug. Blood pressure management sits at the top of that list.
The SPRINT-MIND trial, one of the largest studies to test whether tighter blood pressure control protects cognition, randomized over 9,000 people to a systolic target below 120 mmHg versus the standard target below 140 mmHg. Intensive control did not significantly reduce the risk of full-blown dementia during the study period, but it did reduce the risk of mild cognitive impairment by 19%. That finding matters because mild cognitive impairment often precedes dementia, and preventing that transition is a meaningful goal. For someone already diagnosed with vascular dementia, keeping blood pressure well controlled helps prevent new strokes and further damage to small blood vessels in the brain.
Cholesterol and Statin Therapy
High cholesterol contributes to the atherosclerosis that narrows and blocks blood vessels supplying the brain. Current guidelines recommend lowering LDL cholesterol below 70 mg/dL in people who have had a stroke caused by atherosclerosis. The TST trial, which enrolled nearly 2,900 patients with recent stroke or mini-stroke, confirmed that hitting this more aggressive LDL target reduced the risk of subsequent cardiovascular events compared to a more relaxed target of 90 to 110 mg/dL.
For someone with vascular dementia, statin therapy serves a preventive role. It won’t reverse existing cognitive damage, but it reduces the likelihood of new strokes that would cause further decline.
Antiplatelet Medications and Stroke Prevention
Many people with vascular dementia are prescribed blood thinners or antiplatelet medications like aspirin or clopidogrel. The logic is straightforward: if small strokes or mini-strokes caused the dementia, preventing additional ones should slow progression. Most doctors follow standard secondary stroke prevention guidelines for these patients.
The evidence specifically linking antiplatelet therapy to slower cognitive decline in vascular dementia is limited and mostly indirect. Aspirin and cilostazol have been studied for this purpose, but the data remain preliminary. Still, for patients with a history of stroke or transient ischemic attack, antiplatelet therapy is generally part of the treatment plan because the cardiovascular benefits are well established even if the direct cognitive benefits are harder to prove.
Diabetes and Blood Sugar Management
Poorly controlled diabetes significantly raises the risk of vascular dementia and accelerates its progression. Higher HbA1c levels, a marker of long-term blood sugar control, are associated with worse cognitive performance. Research on German health claims data found that insulin-dependent patients had over three and a half times the dementia risk compared to those not on diabetes medications, while patients on oral diabetes medications alone had a risk that was not significantly elevated. This likely reflects disease severity rather than the medications themselves, but some evidence suggests that metformin in particular may be associated with a reduced dementia risk.
The practical point is that if you have diabetes alongside vascular dementia, keeping blood sugar well managed with the simplest effective regimen is an important part of protecting remaining cognitive function.
What “Best Treatment” Really Means
The honest answer to “what is the best medication” is that no single pill treats vascular dementia effectively on its own. The cognitive medications, donepezil, galantamine, and memantine, offer small and sometimes barely noticeable benefits. Their value lies in being the only options available for directly addressing cognitive symptoms, and for some individuals the effect may be more meaningful than the average trial result suggests.
The medications that likely matter most are the ones targeting the root cause: blood pressure drugs, statins, antiplatelet agents, and diabetes medications. These won’t appear on a list of “dementia drugs,” but they address the vascular damage driving the disease. A comprehensive approach that combines a cholinesterase inhibitor or memantine with tight cardiovascular risk management represents the current standard of care, even though none of these interventions can reverse the cognitive losses that have already occurred.